Strategic Investment in Growth Areas and New Product Launches Through R&D
First written in FY2016. 29 of 37 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「R&D expenses for the fiscal year were ¥4,728 million, equivalent to 3.4% of net sales.」
The company maintained its policy of improving its R&D structure, establishing new technologies, and launching new products in a timely manner, and updated R&D expenses from ¥4,221 million in the previous fiscal year to ¥4,728 million. - FY2026-H1RestatedAnnual report
「R&D activities totaled ¥2,477 million in the six-month interim consolidated accounting period. There was no material change in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company disclosed R&D expenses of ¥2,477 million for the interim consolidated accounting period and stated that there had been no material change in its R&D activities. - FY2025RestatedAnnual report
「The Group has pursued its R&D activities in line with its management philosophy of devoting itself to its social mission and contributing to the advancement of medicine through the development of medical electronic equipment, while always keeping in mind the need to meet user needs. It will continue to pursue this philosophy more actively. In addition, it intends to improve the structure of its R&D organization, establish new technologies, and bring new products to market in a timely manner, thereby further strengthening its management base. R&D expenses for the fiscal year were ¥4,221 million, equivalent to 3.0% of net sales.」
The company stated its policy of continuing to improve its R&D structure, establish new technologies, and launch new products in a timely manner, and disclosed R&D expenses of ¥4,221 million, equivalent to 3.0% of net sales. - FY2025-H1RestatedAnnual report
「R&D activities totaled ¥1,718 million in the six-month interim consolidated accounting period. There was no material change in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company disclosed R&D expenses of ¥1,718 million and stated that there had been no material change in its R&D activities. - FY2024RestatedAnnual report
「The Group has pursued its R&D activities in line with its management philosophy of devoting itself to its social mission and contributing to the advancement of medicine through the development of medical electronic equipment, while always keeping in mind the need to meet user needs. It will continue to pursue this philosophy more actively. In addition, it intends to improve the structure of its R&D organization, establish new technologies, and bring new products to market in a timely manner, thereby further strengthening its management base. R&D expenses for the fiscal year were ¥4,740 million, equivalent to 3.4% of net sales.」
The company stated its policy of continuing to improve its R&D structure, establish new technologies, and launch new products in a timely manner, and disclosed R&D expenses of ¥4,740 million, equivalent to 3.4% of net sales. - FY2024-Q3RestatedAnnual report
「R&D activities totaled ¥3,443 million in the nine months ended the third quarter. There was no material change in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company disclosed R&D expenses of ¥3,443 million for the nine months ended the third quarter and stated that there had been no material change in its R&D activities. - FY2024-Q2RestatedAnnual report
「R&D activities totaled ¥2,278 million in the six months ended the second quarter. There was no material change in the status of the Group's R&D activities during the six months ended the second quarter.」
The company disclosed R&D expenses of ¥2,278 million for the six months ended the second quarter and stated that there had been no material change in its R&D activities. - FY2024-Q1RestatedAnnual report
「R&D activities totaled ¥1,046 million in the three months ended the first quarter. There was no material change in the status of the Group's R&D activities during the three months ended the first quarter.」
The company disclosed first-quarter R&D expenses of ¥1,046 million and stated that there had been no material change in its R&D activities. - FY2023AdvancedAnnual report
「R&D expenses for the fiscal year were ¥3,785 million, equivalent to 2.8% of net sales, with the breakdown as follows. As a development achievement, the biosensing equipment segment launched a Holter recorder compliant with pediatric specifications for children weighing less than 10 kg, with a focus on reducing the burden on patients and operators.」
The company recorded R&D expenses of ¥3,785 million, equivalent to 2.8% of net sales, and disclosed the launch of specific new products, including a pediatric Holter recorder, a central monitor with analysis functions, and an air purification, sterilization and deodorization system. - FY2023-Q3RestatedAnnual report
「R&D activities totaled ¥2,683 million in the nine months ended the third quarter. There was no material change in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company disclosed R&D expenses of ¥2,683 million for the nine months ended the third quarter and stated that there had been no material change in its R&D activities. - FY2023-Q2RestatedAnnual report
「R&D activities totaled ¥1,664 million in the six months ended the second quarter. There was no material change in the status of the Group's R&D activities during the six months ended the second quarter.」
The company disclosed R&D expenses of ¥1,664 million and stated that there had been no material change in its R&D activities. - FY2023-Q1RestatedAnnual report
「R&D activities totaled ¥697 million in the three months ended the first quarter. There was no material change in the status of the Group's R&D activities during the three months ended the first quarter.」
The company disclosed first-quarter R&D expenses of ¥697 million and stated that there had been no material change in its R&D activities. - FY2022AdvancedAnnual report
「R&D expenses for the fiscal year were ¥3,448 million, equivalent to 2.6% of net sales, with the breakdown as follows. As a development achievement, the biosensing equipment segment launched an ECG testing device that supports ACS (acute coronary syndrome) diagnosis and offers improved detection of Brugada-type ECG patterns.」
The company recorded R&D expenses of ¥3,448 million, equivalent to 2.6% of net sales, and launched an ECG testing device with ACS diagnostic support and Brugada-type ECG detection functions. - FY2022-Q3RestatedAnnual report
「R&D activities totaled ¥2,274 million in the nine months ended the third quarter. There was no material change in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company disclosed R&D expenses of ¥2,274 million for the nine months ended the third quarter and stated that there had been no material change in its R&D activities. - FY2022-Q2RestatedAnnual report
「R&D activities totaled ¥1,427 million in the six months ended the second quarter. There was no material change in the status of the Group's R&D activities during the six months ended the second quarter.」
The company disclosed R&D expenses of ¥1,427 million and stated that there had been no material change in its R&D activities. - FY2022-Q1RestatedAnnual report
「R&D activities totaled ¥594 million in the three months ended the first quarter. There was no material change in the status of the Group's R&D activities during the three months ended the first quarter.」
The company disclosed first-quarter R&D expenses of ¥594 million and stated that there had been no material change in its R&D activities. - FY2021AdvancedAnnual report
「R&D expenses for the fiscal year were ¥3,296 million, equivalent to 2.2% of net sales, with the breakdown as follows. As a development achievement, the biosensing equipment segment launched a Holter recorder to support more precise arrhythmia diagnosis.」
R&D expenses totaled ¥3,296 million, equivalent to 2.2% of net sales. The company launched a Holter recorder supporting high-sampling-rate recording at 1,000 Hz and ECG recording for up to 7 days, as well as a blood pressure and pulse-wave testing device. - FY2021-Q3RestatedAnnual report
「R&D activities totaled ¥2,383 million in the nine months ended the third quarter. There was no material change in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company disclosed R&D expenses of ¥2,383 million for the nine months ended the third quarter and stated that there had been no material change in its R&D activities. - FY2021-Q2RestatedAnnual report
「R&D activities totaled ¥1,670 million in the six months ended the second quarter. There was no material change in the status of the Group's R&D activities during the six months ended the second quarter.」
The company disclosed R&D expenses of ¥1,670 million for the six months ended the second quarter and stated that there had been no material change in its R&D activities. - FY2021-Q1RestatedAnnual report
「R&D activities totaled ¥865 million in the three months ended the first quarter. There was no material change in the status of the Group's R&D activities during the three months ended the first quarter.」
The company disclosed first-quarter R&D expenses of ¥865 million and stated that there had been no material change in its R&D activities. - FY2020AdvancedAnnual report
「R&D expenses for the fiscal year were ¥2,798 million, equivalent to 2.1% of net sales, with the breakdown as follows. As a development achievement, the biosensing equipment segment launched an ECG analyzer designed to pursue improved efficiency and quality in ECG testing.」
The company recorded R&D expenses of ¥2,798 million, equivalent to 2.1% of net sales, and launched an ECG analyzer, a blood pressure and pulse-wave testing device, and a fingertip clip pulse oximeter, among other products. - FY2020-Q3RestatedAnnual report
「R&D activities totaled ¥1,721 million in the nine months ended the third quarter. There was no material change in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company disclosed R&D expenses of ¥1,721 million for the nine months ended the third quarter and stated that there had been no material change in its R&D activities. - FY2020-Q2RestatedAnnual report
「R&D activities totaled ¥1,095 million in the six months ended the second quarter. There was no material change in the status of the Group's R&D activities during the six months ended the second quarter.」
The company disclosed R&D expenses of ¥1,095 million for the six months ended the second quarter and stated that there had been no material change in its R&D activities. - FY2020-Q1RestatedAnnual report
「R&D activities totaled ¥492 million in the three months ended the first quarter. There was no material change in the status of the Group's R&D activities during the three months ended the first quarter.」
The company disclosed first-quarter R&D expenses of ¥492 million and stated that there had been no material change in its R&D activities. - FY2019AdvancedAnnual report
「As a development achievement, the biosensing equipment segment launched an ECG analyzer that supports a variety of applications.」
The company recorded R&D expenses of ¥2,323 million, equivalent to 1.8% of net sales, and launched an ECG analyzer, a Holter recorder, diagnostic electrode catheters, and an oxygen concentrator with a remote monitoring function, among other products. - FY2019-Q3RestatedAnnual report
「R&D activities totaled ¥1,565 million in the nine months ended the third quarter. There was no material change in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company disclosed R&D expenses of ¥1,565 million for the nine months ended the third quarter and stated that there had been no material change in its R&D activities. - FY2019-Q2RestatedAnnual report
「R&D activities totaled ¥1,029 million in the six months ended the second quarter. There was no material change in the status of the Group's R&D activities during the six months ended the second quarter.」
The company disclosed R&D expenses of ¥1,029 million and stated that there had been no material change in its R&D activities. - FY2019-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year totaled ¥462 million. There were no material changes in the status of the Group’s research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The company disclosed first-quarter R&D expenses of ¥462 million and stated that there had been no material change in its R&D activities. - FY2018AdvancedAnnual report
「Research and development expenses for the current consolidated fiscal year were ¥2,550 million, or 2.0% of net sales, as detailed below. As a development achievement, the Biosignal Testing Equipment Division launched a lightweight, compact and fully waterproof long-term ECG recorder capable of continuously recording a single-lead full waveform for up to 14 days, including during bathing, without replacing the battery.」
The Company recorded research and development expenses of ¥2,550 million, or 2.0% of net sales, and launched several new products, including a long-term ECG recorder capable of recording for up to 14 days. - FY2018-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year totaled ¥1,630 million. There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The Company disclosed cumulative third-quarter research and development expenses of ¥1,630 million and stated that there were no material changes in the status of its research and development activities. - FY2018-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year totaled ¥1,067 million. There were no material changes in the status of the Group’s research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
The Company disclosed cumulative second-quarter research and development expenses of ¥1,067 million and stated that there were no material changes in the status of its research and development activities. - FY2018-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year totaled ¥538 million. There were no material changes in the status of the Group’s research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The Company disclosed first-quarter research and development expenses of ¥538 million and stated that there were no material changes in the status of its research and development activities. - FY2017AdvancedAnnual report
「As development achievements, the Biosignal Testing Equipment Division launched an electrocardiograph with analysis functions featuring an auto-capture function that automatically extracts, records and analyzes low-noise ECG waveforms, and a data comparison function that enables simultaneous monitoring during testing of ECG waveforms and the results of the previous test. Research and development expenses for the current consolidated fiscal year were ¥2,581 million, or 2.1% of net sales, as detailed below.」
The Company recorded research and development expenses of ¥2,581 million, or 2.1% of net sales, and disclosed the launch of specific new products, including an electrocardiograph with analysis functions. - FY2017-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year totaled ¥1,687 million. There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The Company disclosed research and development expenses of ¥1,687 million and stated that there were no material changes in the status of its research and development activities. - FY2017-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year totaled ¥1,118 million. There were no material changes in the status of the Group’s research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
The Company disclosed research and development expenses of ¥1,118 million but stated that there were no material changes in the status of its research and development activities. - FY2017-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year totaled ¥538 million. There were no material changes in the status of the Group’s research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The Company disclosed quarterly research and development expenses of ¥538 million and stated that there were no material changes in the status of its research and development activities. - FY2016First statedAnnual report
「Through strategic investment in fields with expected growth and effective research and development initiatives, we will pursue comprehensive proposals for medical institutions and strengthen our community-based infrastructure in home healthcare. We also aim to enhance the Group’s management control system by strengthening governance and compliance systems and revitalizing the organization through human resource development.」
This lists investment in growth fields, research and development, home healthcare, governance and human resource development as means of strengthening the management foundation.